The AstraZeneca cancer drug spinoff floated above its range in an upsized initial public offering and now has a market cap topping $2bn.

Switzerland-based oncology therapy developer ADC Therapeutics went public on Friday having raised almost $233m in an initial public offering, nine years after it was spun off from pharmaceutical firm AstraZeneca. The company issued more than 12.2 million shares on the New York Stock Exchange, upsized from nearly 10.3 million. They were priced at $19.00 each,…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.